Premarket Decliner
RNAZ Transcode Therapeutics5.28-0.15-2.8%
Premarket:4.11-1.17 (-22.2%)
TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer
PRNewswireWed, 3-Jun 8:04 AM
After Hours Gainer
RNAZ Transcode Therapeutics3.21-0.79-19.8%
After Hours:6.00+2.79 (+86.9%)
TransCode Therapeutics Reports Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Glioblastoma
Globe NewswireTue, 6-Jun 4:01 PM
Premarket Gainer
RNAZ Transcode Therapeutics2.62+0.17+6.9%
Premarket:3.26+0.64 (+24.4%)
TransCode Therapeutics Announces Publication in Cancer Nanotechnology of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Metastatic Breast Cancer
Business WireThu, 23-Sep 7:30 AM
